• Home
  • Our Pipeline
  • About Us
  • Our Team
  • News
  • Contact Us

We are dedicated to the preventing and slowing the progression of dementia, which is the largest future public health issue.





Novel first-in-class therapeutic for Systemic Sclerosis





Our story



We have discovered that diminished expression of the mitochondrial protein SIRT3 (Sirtuin 3) is a common feature of many neuro-degenerative diseases and by restoring SIRT3 with our new class of disease modifying therapeutics we can protect and prevent the progression of neuro-degenerative diseases such as Dementia, Parkinson's Disease, and Metabolic Disorder.


SIRT3 is a member of the sirtuin family of proteins and involved in the regulation of cellular processes such as aging, metabolism, and stress resistance. SIRT3 is an important for the normal function and restoration of function in neurodegenerative diseases.


Our lead compound AN-018 has been validated in extensive preclinical research and development to protect and restore health cellular function in neurodegenerative, age related, and metabolic diseases.


We are a late pre-clinical stage pharmaceutical company with multiple compounds in development that were discovered at Emory University. We are a privately-funded company and have received significant support from the Georgia Research Alliance, GRA Venture Fund, and the BioMed Investor Network.





Our vision



Our primary focus is on creating the “Statin” for prevention of the progression neurodegenerative diseases. Through our continuing research we have validated the therapeutic potential of our lead program in multiple preclinical efficacy studies.


Neurological Diseases

-Dementia

-HIV/AIDS Neurocognitive Disorder

-Parkinson's Disease

-Methamphetamine Addiction​

-Retinitis Pigmentosa





​ABOUT neurodegenerative diseases



Neurodegenerative diseases affect millions of people worldwide. Alzheimer’s disease and Parkinson’s disease are the most common neurodegenerative diseases. In the United States, as many as 7 million people may have Alzheimer’s/Dementia, according to a report from the Alzheimer's Disease Association in 2022.


Nearly a million Americans are living with Parkinson’s disease, according to the Parkinson’s Foundation. Neurodegenerative diseases occur when nerve cells in the brain or peripheral nervous system lose function over time and ultimately die. The likelihood of developing a neurodegenerative disease rises dramatically with age. In the coming decades, more Americans may be affected by neurodegenerative diseases, especially as life expectancy increases.


Scientists recognize that the combination of a person’s genes, and environment contributes to their risk of developing a neurodegenerative disease. For example, someone might have a gene that makes them more susceptible to Parkinson’s disease, but their environmental exposures can affect whether, when, and how severely they are affected.


We must improve our understanding of what causes neurodegenerative diseases and develop new approaches for treatment and prevention.


​




Our Partners



307 Mary St
Clarkesville, GA 30523


CALL: 678-812-1492

Phone number: 678-812-1492 email: info@accuitis.com